Aperio Group’s Crescent Biopharma CBIO Stock Holding History

Aperio Group’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-41	Closed	-$49K	–	2491
2019 Q2	$49K	Buy	+41	New	+$49K	﹤0.01%	2536

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Aperio Group's CBIO Position: Q3 2019 in Review

Aperio Group sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 41 shares — an estimated $49K sold.

Aperio Group first reported a position in CBIO in Q2 2019 and held it in 1 quarter. The position peaked at $49K in Q2 2019. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

Aperio Group reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 41 Crescent Biopharma shares in Q3 2019, an estimated $49K.
Aperio Group first reported a position in Crescent Biopharma in Q2 2019 and held it in 1 quarter.
Aperio Group's Crescent Biopharma position peaked at $49K in Q2 2019.
75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.